1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Real World Evidence Solutions Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Real World Evidence Solutions Market, by Product Type
8.1.1. Data Solution
8.1.1.1. Market Revenue and Forecast
8.1.2. Analytics & Software Platform
8.1.2.1. Market Revenue and Forecast
8.1.3. Consulting & Managed Service
8.1.3.1. Market Revenue and Forecast
9.1. Real World Evidence Solutions Market, by Service Type
9.1.1. Observational Studie
9.1.1.1. Market Revenue and Forecast
9.1.2. Pragmatic / Hybrid Clinical Trial
9.1.2.1. Market Revenue and Forecast
9.1.3. Health Economics & Outcomes Research (HEOR)
9.1.3.1. Market Revenue and Forecast
10.1. Real World Evidence Solutions Market, by End User
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Biotechnology Companies
10.1.2.1. Market Revenue and Forecast
10.1.3. Medical Device & Diagnostics Companie
10.1.3.1. Market Revenue and Forecast
10.1.4. Contract Research Organizations (CROs)
10.1.4.1. Market Revenue and Forecast
10.1.5. Payers / Health Systems
10.1.5.1. Market Revenue and Forecast
11.1. Real World Evidence Solutions Market, by Therapeutic Area
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Rare / Orphan Diseases
11.1.2.1. Market Revenue and Forecast
11.1.3. Cardiovascular & Metabolic Diseases
11.1.3.1. Market Revenue and Forecast
11.1.4. Immunology & Autoimmune Disorders
11.1.4.1. Market Revenue and Forecast
11.1.5. Neurology / CNS Disorders
11.1.5.1. Market Revenue and Forecast
12.1. Real World Evidence Solutions Market, by Deployment Model
12.1.1. On-Premise Solutions
12.1.1.1. Market Revenue and Forecast
12.1.2. Cloud-Based Solutions
12.1.2.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product Type
13.1.2. Market Revenue and Forecast, by Service Type
13.1.3. Market Revenue and Forecast, by End User
13.1.4. Market Revenue and Forecast, by Therapeutic Area
13.1.5. Market Revenue and Forecast, by Deployment Model
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product Type
13.1.6.2. Market Revenue and Forecast, by Service Type
13.1.6.3. Market Revenue and Forecast, by End User
13.1.6.4. Market Revenue and Forecast, by Therapeutic Area
13.1.6.5. Market Revenue and Forecast, by Deployment Model
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product Type
13.1.7.2. Market Revenue and Forecast, by Service Type
13.1.7.3. Market Revenue and Forecast, by End User
13.1.7.4. Market Revenue and Forecast, by Therapeutic Area
13.1.7.5. Market Revenue and Forecast, by Deployment Model
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product Type
13.2.2. Market Revenue and Forecast, by Service Type
13.2.3. Market Revenue and Forecast, by End User
13.2.4. Market Revenue and Forecast, by Therapeutic Area
13.2.5. Market Revenue and Forecast, by Deployment Model
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product Type
13.2.6.2. Market Revenue and Forecast, by Service Type
13.2.6.3. Market Revenue and Forecast, by End User
13.2.7. Market Revenue and Forecast, by Therapeutic Area
13.2.8. Market Revenue and Forecast, by Deployment Model
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product Type
13.2.9.2. Market Revenue and Forecast, by Service Type
13.2.9.3. Market Revenue and Forecast, by End User
13.2.10. Market Revenue and Forecast, by Therapeutic Area
13.2.11. Market Revenue and Forecast, by Deployment Model
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product Type
13.2.12.2. Market Revenue and Forecast, by Service Type
13.2.12.3. Market Revenue and Forecast, by End User
13.2.12.4. Market Revenue and Forecast, by Therapeutic Area
13.2.13. Market Revenue and Forecast, by Deployment Model
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product Type
13.2.14.2. Market Revenue and Forecast, by Service Type
13.2.14.3. Market Revenue and Forecast, by End User
13.2.14.4. Market Revenue and Forecast, by Therapeutic Area
13.2.15. Market Revenue and Forecast, by Deployment Model
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product Type
13.3.2. Market Revenue and Forecast, by Service Type
13.3.3. Market Revenue and Forecast, by End User
13.3.4. Market Revenue and Forecast, by Therapeutic Area
13.3.5. Market Revenue and Forecast, by Deployment Model
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product Type
13.3.6.2. Market Revenue and Forecast, by Service Type
13.3.6.3. Market Revenue and Forecast, by End User
13.3.6.4. Market Revenue and Forecast, by Therapeutic Area
13.3.7. Market Revenue and Forecast, by Deployment Model
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product Type
13.3.8.2. Market Revenue and Forecast, by Service Type
13.3.8.3. Market Revenue and Forecast, by End User
13.3.8.4. Market Revenue and Forecast, by Therapeutic Area
13.3.9. Market Revenue and Forecast, by Deployment Model
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product Type
13.3.10.2. Market Revenue and Forecast, by Service Type
13.3.10.3. Market Revenue and Forecast, by End User
13.3.10.4. Market Revenue and Forecast, by Therapeutic Area
13.3.10.5. Market Revenue and Forecast, by Deployment Model
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product Type
13.3.11.2. Market Revenue and Forecast, by Service Type
13.3.11.3. Market Revenue and Forecast, by End User
13.3.11.4. Market Revenue and Forecast, by Therapeutic Area
13.3.11.5. Market Revenue and Forecast, by Deployment Model
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product Type
13.4.2. Market Revenue and Forecast, by Service Type
13.4.3. Market Revenue and Forecast, by End User
13.4.4. Market Revenue and Forecast, by Therapeutic Area
13.4.5. Market Revenue and Forecast, by Deployment Model
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product Type
13.4.6.2. Market Revenue and Forecast, by Service Type
13.4.6.3. Market Revenue and Forecast, by End User
13.4.6.4. Market Revenue and Forecast, by Therapeutic Area
13.4.7. Market Revenue and Forecast, by Deployment Model
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product Type
13.4.8.2. Market Revenue and Forecast, by Service Type
13.4.8.3. Market Revenue and Forecast, by End User
13.4.8.4. Market Revenue and Forecast, by Therapeutic Area
13.4.9. Market Revenue and Forecast, by Deployment Model
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product Type
13.4.10.2. Market Revenue and Forecast, by Service Type
13.4.10.3. Market Revenue and Forecast, by End User
13.4.10.4. Market Revenue and Forecast, by Therapeutic Area
13.4.10.5. Market Revenue and Forecast, by Deployment Model
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product Type
13.4.11.2. Market Revenue and Forecast, by Service Type
13.4.11.3. Market Revenue and Forecast, by End User
13.4.11.4. Market Revenue and Forecast, by Therapeutic Area
13.4.11.5. Market Revenue and Forecast, by Deployment Model
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product Type
13.5.2. Market Revenue and Forecast, by Service Type
13.5.3. Market Revenue and Forecast, by End User
13.5.4. Market Revenue and Forecast, by Therapeutic Area
13.5.5. Market Revenue and Forecast, by Deployment Model
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product Type
13.5.6.2. Market Revenue and Forecast, by Service Type
13.5.6.3. Market Revenue and Forecast, by End User
13.5.6.4. Market Revenue and Forecast, by Therapeutic Area
13.5.7. Market Revenue and Forecast, by Deployment Model
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product Type
13.5.8.2. Market Revenue and Forecast, by Service Type
13.5.8.3. Market Revenue and Forecast, by End User
13.5.8.4. Market Revenue and Forecast, by Therapeutic Area
13.5.8.5. Market Revenue and Forecast, by Deployment Model
14.1. IQVIA Holdings Inc
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Merative
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Optum Inc
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. ICON plc
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Syneos Health Inc
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Parexel International Corporation
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Tata Consultancy Services
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Oracle Corporation
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Elevance Health Inc
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. SAS Institute Inc
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
